The primary analysis will involve comparison of Reveal G4 results for anti-HIV-1 in each sample matrix (fingerstick whole blood and venous whole blood) with the subject's HIV-1 antibody status as determined by FDA-approved assays. Based on the above, the sensitivity and specificity of Reveal G4 will be determined with corresponding two-sided 95% confidence intervals for both fingerstick and venous whole blood.